Project Grant R41GM159477
Award Date
6/5/25
Completion Date
5/31/26
Dollars Obligated
$350K
Federal Agency
National Institute of General Medical Sciences
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The National Institute of General Medical Sciences (NIGMS) awarded a $300,518 Project Grant under CFDA Program 93.859 (Biomedical Research and Research Training) to E&E Bioclub LLC in Indianapolis, IN. The project aims to develop an all-in-one platform for intracellular overproduction of long, single-strand mRNA. This is intended to address challenges with current mRNA manufacturing methods, such as the cost and scalability constraints of in vitro transcription and the difficulty in...
The National Science Foundation (NSF) awarded a $274,980 SBIR Phase I Project Grant to Cisterna Biologics, Inc. to develop a novel platform for cost-efficient mRNA production in yeast. The project aims to transform yeast cells into efficient mRNA factories and utilize advanced chromatographic techniques for purification, with the goal of reducing mRNA manufacturing costs by 90% compared to current in vitro transcription methods. Key technical objectives include demonstrating stable mRNA fusion...
The National Institute of General Medical Sciences (NIGMS) awarded a $305,892 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Dotquant LLC, a biotechnology research and development company, to develop a new in vitro transcription kit for high-yield synthesis of chemically modified RNA. The project aims to combine the benefits of wild-type T7 RNA polymerase, which has high efficiency and low cost, with the ability of mutant T7 RNA polymerases to...
This $700,000 federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to create the next generation of RNA interference (RNAi) therapeutics and develop an in vivo model for evaluating their efficacy and biodistribution. The key products and services to be delivered include: Generating novel RNAi-based therapeutic biologics by coupling optimized siRNAs or artificial miRNA scaffolds to...
The Project Grant award R01GM155969, funded by the National Institute of General Medical Sciences (NIGMS) under CFDA 93.859 Biomedical Research and Research Training program, supports the development of a novel biomaterial platform for effective intracellular delivery of messenger RNA (mRNA) therapeutics and research tools. The $424,451 award to the University of Connecticut aims to optimize the biointerface properties of DNA-inspired Janus base biomaterials using computational modeling to...
The National Institute of General Medical Sciences (NIGMS) awarded a $302,605 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Chimerna Therapeutics, Inc., a biotechnology company located in New York, NY. The grant funding will support the development of a scalable and low-cost method for semi-synthesis of site-specifically labeled circular RNAs (circRNAs). The key objectives are to: 1) optimize a bacterial strain and expression conditions for high...
The National Institute of General Medical Sciences (NIGMS) awarded a $917,454 Project Grant under CFDA 93.859, Biomedical Research and Research Training, to Integral Molecular Inc. The grant supports the development of a novel Membrane Proteome Array (MPA) technology for specificity screening and profiling of biotherapeutics like monoclonal antibodies and CAR-T cell therapies. The MPA represents 93% of the human extracellular proteome expressed in native conformation, providing a more...
This federal Project Grant award, with a total funding amount of $658,165, was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859). The award aims to support research that focuses on understanding the fundamental mechanisms of ribosome function and mRNA regulation, with a specific emphasis on the role of ions and antibiotics. Key areas of investigation include: Elucidating the mechanisms by which initial...
This Project Grant award of $388,621 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) will support the development of novel molecular designs with therapeutic potential. The key objectives are: Developing ligand-heterocycle conjugates as targeted RNA degraders with rapid kinetics and selectivity for cancer-associated G-quadruplexes. Engineering nucleic acid polymers with (thio)phosphoramidate backbones as biostable...
This $842,151 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the development of an improved, low-endotoxin E. coli strain for the production of biological products such as recombinant proteins and plasmid DNA. The awardee, Scarab Genomics LLC, a biotechnology company in Madison, Wisconsin, will use genetic engineering techniques to substantially lower the level of contaminating endotoxin...